ArticleFrontiers in pharmacology2026
CRIP1 promotes docetaxel resistance and immune-associated cell death modulation in prostate cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Docetaxel resistance is a major barrier to durable disease control in advanced and castration-resistant prostate cancer. There is a pharmacological need to identify biomarkers that not only stratify resistance risk but also nominate tractable regulators whose perturbation can restore taxane sensitivity and suppress resistant phenotypes. Methods: We analyzed docetaxel-resistant prostate cancer cell models to derive resistance-associated transcriptional candidates and used computational prioritization to construct a compact, taxane-resistance-anchored gene set. Associations of the gene set and key candidates with disease progression were evaluated in TCGA-PRAD, which predominantly represents treatment-naïve primary tumors and therefore provides progression relevance rather than treatment-specific response validation. Docetaxel-resistant cell lines were established for functional validation, and CRIP1 was stably silenced to assess effects on drug sensitivity, clonogenic growth, migration, apoptosis, and immune-associated cell-death features. In addition, an LNCaP-DTXr xenograft model was used to evaluate the impact of CRIP1 knockdown on docetaxel response Results: A three-gene, taxane-resistance-anchored signature was derived and showed progression-related associations in TCGA-PRAD. Among candidates, cysteine-rich protein 1 (CRIP1) was consistently upregulated in resistant models and emerged as a top resistance-associated factor. Functionally, CRIP1 knockdown restored docetaxel sensitivity, reduced clonogenic survival and migratory capacity, and enhanced docetaxel-induced apoptosis in resistant prostate cancer cells. Consistently, CRIP1 depletion significantly suppressed tumor growth and reduced tumor burden in docetaxel-treated LNCaP-DTXr xenografts, indicating restored chemosensitivity Conclusion: These findings identify CRIP1 as a functionally validated, pharmacologically relevant mediator of docetaxel resistance in prostate cancer. While independent validation in taxane-treated clinical cohorts is warranted, our results support CRIP1 as a candidate therapeutic target and provide a mechanistic framework connecting taxane resistance with immune-associated cell-death modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.